FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255911888> ?p ?o ?g. }

• W4255911888 endingPage "321" @default.
• W4255911888 startingPage "311" @default.
• W4255911888 abstract "Sodium-dependent glucose transporter-2 (SGLT2) inhibitors such as dapagliflozin induce weight loss, but the mechanism is thought to involve loss of both body fat and skeletal muscle mass. The decrease in skeletal muscle mass may lead to worsening of insulin resistance in type 2 diabetes patients. On the other hand, formula diet (FD) is a low-calorie food containing low carbohydrates, low fat, and sufficient protein, vitamins, and minerals to support a healthy and balanced diet, and is used for the treatment of obesity or diabetes. Therefore, we examine whether the protein supplementation is superior to the fat supplementation in metabolic improvement of the poorly controlled type 2 diabetes patients treated with SGLT2 inhibitor. We compare the therapeutic effects using two types of FD; a high protein FD and a high fat FD. Patients are prescribed dapagliflozin and replacement of one of three meals with FD. We compare high protein FD and high fat FD with respect to improvement of glycemic control while maintaining skeletal muscle mass. We conduct a prospective, multicenter, double-blinded, randomized, controlled, investigator-initiated clinical trial. Patients who satisfy the eligibility criteria will be randomized to two groups (1:1) and prescribed 5 mg of dapagliflozin once daily together with a high protein FD or high fat FD (same number of calories) to replace one of three meals a day (one meal with FD only and two normal meals). The observation period for both groups is 24 weeks. The primary endpoint is the change in HbA1c. This study is ongoing and scheduled to complete in June 2019. The findings of this study will be disseminated through peer-reviewed publications and conference presentations. University Hospital Medical Information Network (UMIN) 000024580. This study was carried out under contract with the specified nonprofit corporation Hokkaido Institute of Health Sciences, based on a grant from AstraZeneca Co., Ltd. and Ono Pharmaceutical Co., Ltd. for an investigator-initiated clinical trial. The authors funded the journals article processing charges." @default.
• W4255911888 created "2022-05-12" @default.
• W4255911888 creator A5007519585 @default.
• W4255911888 creator A5031651975 @default.
• W4255911888 creator A5037848265 @default.
• W4255911888 creator A5039591257 @default.
• W4255911888 creator A5055651368 @default.
• W4255911888 creator A5056777056 @default.
• W4255911888 creator A5060286280 @default.
• W4255911888 creator A5067460231 @default.
• W4255911888 creator A5090061850 @default.
• W4255911888 creator A5090279793 @default.
• W4255911888 date "2018-12-21" @default.
• W4255911888 modified "2023-10-18" @default.
• W4255911888 title "Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus" @default.
• W4255911888 cites W1890354996 @default.
• W4255911888 cites W1966842378 @default.
• W4255911888 cites W1978600011 @default.
• W4255911888 cites W1979896422 @default.
• W4255911888 cites W1984542647 @default.
• W4255911888 cites W1986888801 @default.
• W4255911888 cites W1987282451 @default.
• W4255911888 cites W1991112339 @default.
• W4255911888 cites W1999464889 @default.
• W4255911888 cites W2006676076 @default.
• W4255911888 cites W2007296513 @default.
• W4255911888 cites W2015398894 @default.
• W4255911888 cites W2019127409 @default.
• W4255911888 cites W2048778380 @default.
• W4255911888 cites W2070569494 @default.
• W4255911888 cites W2071870756 @default.
• W4255911888 cites W2077636750 @default.
• W4255911888 cites W2081558025 @default.
• W4255911888 cites W2103593743 @default.
• W4255911888 cites W2135545720 @default.
• W4255911888 cites W2139617669 @default.
• W4255911888 cites W2150855258 @default.
• W4255911888 cites W2157405334 @default.
• W4255911888 cites W2166613497 @default.
• W4255911888 cites W2167245776 @default.
• W4255911888 cites W2217349032 @default.
• W4255911888 cites W2525669451 @default.
• W4255911888 cites W2528781334 @default.
• W4255911888 cites W2737522672 @default.
• W4255911888 cites W2886580697 @default.
• W4255911888 doi "https://doi.org/10.1007/s13300-018-0555-5" @default.
• W4255911888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30574667" @default.
• W4255911888 hasPublicationYear "2018" @default.
• W4255911888 type Work @default.
• W4255911888 citedByCount "3" @default.
• W4255911888 countsByYear W42559118882020 @default.
• W4255911888 countsByYear W42559118882021 @default.
• W4255911888 countsByYear W42559118882023 @default.
• W4255911888 crossrefType "journal-article" @default.
• W4255911888 hasAuthorship W4255911888A5007519585 @default.
• W4255911888 hasAuthorship W4255911888A5031651975 @default.
• W4255911888 hasAuthorship W4255911888A5037848265 @default.
• W4255911888 hasAuthorship W4255911888A5039591257 @default.
• W4255911888 hasAuthorship W4255911888A5055651368 @default.
• W4255911888 hasAuthorship W4255911888A5056777056 @default.
• W4255911888 hasAuthorship W4255911888A5060286280 @default.
• W4255911888 hasAuthorship W4255911888A5067460231 @default.
• W4255911888 hasAuthorship W4255911888A5090061850 @default.
• W4255911888 hasAuthorship W4255911888A5090279793 @default.
• W4255911888 hasBestOaLocation W42559118881 @default.
• W4255911888 hasConcept C126322002 @default.
• W4255911888 hasConcept C134018914 @default.
• W4255911888 hasConcept C168563851 @default.
• W4255911888 hasConcept C203092338 @default.
• W4255911888 hasConcept C2777180221 @default.
• W4255911888 hasConcept C2777391703 @default.
• W4255911888 hasConcept C2777422806 @default.
• W4255911888 hasConcept C2780473172 @default.
• W4255911888 hasConcept C40438245 @default.
• W4255911888 hasConcept C511355011 @default.
• W4255911888 hasConcept C544821477 @default.
• W4255911888 hasConcept C555293320 @default.
• W4255911888 hasConcept C71924100 @default.
• W4255911888 hasConceptScore W4255911888C126322002 @default.
• W4255911888 hasConceptScore W4255911888C134018914 @default.
• W4255911888 hasConceptScore W4255911888C168563851 @default.
• W4255911888 hasConceptScore W4255911888C203092338 @default.
• W4255911888 hasConceptScore W4255911888C2777180221 @default.
• W4255911888 hasConceptScore W4255911888C2777391703 @default.
• W4255911888 hasConceptScore W4255911888C2777422806 @default.
• W4255911888 hasConceptScore W4255911888C2780473172 @default.
• W4255911888 hasConceptScore W4255911888C40438245 @default.
• W4255911888 hasConceptScore W4255911888C511355011 @default.
• W4255911888 hasConceptScore W4255911888C544821477 @default.
• W4255911888 hasConceptScore W4255911888C555293320 @default.
• W4255911888 hasConceptScore W4255911888C71924100 @default.
• W4255911888 hasIssue "1" @default.
• W4255911888 hasLocation W42559118881 @default.
• W4255911888 hasLocation W42559118882 @default.
• W4255911888 hasLocation W42559118883 @default.
• W4255911888 hasLocation W42559118884 @default.
• W4255911888 hasOpenAccess W4255911888 @default.
• W4255911888 hasPrimaryLocation W42559118881 @default.

• next